Literature DB >> 6445374

beta-Endorphin and beta-lipotropin plasma levels in hirsute women: correlation with body weight.

J R Givens, E Wiedemann, R N Andersen, A E Kitabchi.   

Abstract

Based on the findings of elevated circulating beta-endorphin (beta-END) levels in genetically obese (fa/fa) fats and the reversal of the overeating of genetically obese (ob/ob) mice by naloxone, circulating beta-END and beta-lipotropin (beta-LPH) levels were measured in 8 hirsute, hyperandrogenic, oligo-amenorrheic women of varying weights. Circulating beta-END and beta-LPH levels were significantly elevated (p less than .001) above the levels in nonobese control subjects and were positively correlated with body weight (p less than .025). Based on these data and indirect evidence in the literature, we propose a role may exist for beta-END and/or beta-LPH in human obesity and in adrenal androgen secretion.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6445374     DOI: 10.1210/jcem-50-5-975

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Exercise and secondary amenorrhoea linked through endogenous opioids.

Authors:  M T Ruffin; R E Hunter; E A Arendt
Journal:  Sports Med       Date:  1990-08       Impact factor: 11.136

2.  The effects of glucose ingestion and fasting on plasma immunoreactive beta-endorphin, adrenocorticotropic hormone and cortisol in obese subjects.

Authors:  S Balon-Perin; J Kolanowski; A Berbinschi; P Franchimont; J M Ketelslegers
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

3.  Orocecal transit delay in obese patients.

Authors:  G Basilisco; G Camboni; A Bozzani; P Vita; S Doldi; P A Bianchi
Journal:  Dig Dis Sci       Date:  1989-04       Impact factor: 3.199

4.  Effects of obesity on gonadotropin secretion in patients with polycystic ovarian disease.

Authors:  R Paradisi; S Venturoli; R Pasquali; M Capelli; E Porcu; R Fabbri; C Flamigni
Journal:  J Endocrinol Invest       Date:  1986-04       Impact factor: 4.256

Review 5.  Opioid peptides and metabolic regulation.

Authors:  D Giugliano; R Torella; P J Lefèbvre; F D'Onofrio
Journal:  Diabetologia       Date:  1988-01       Impact factor: 10.122

6.  Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans.

Authors:  G Plewe; U Schneider; U Krause; J Beyer
Journal:  J Endocrinol Invest       Date:  1987-04       Impact factor: 4.256

7.  Increased DHEAs levels in PCO syndrome: evidence for the existence of two subgroups of patients.

Authors:  E Carmina; F Rosato; A Jannì
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

8.  Pituitary and adrenal response to ovine corticotropin-releasing hormone in women with polycystic ovarian syndrome.

Authors:  A Mongioì; M Macchi; E Vicari; M C Fornito; A E Calogero; C Riccioli; G Minacapilli; M L Moncada; R D'Agata
Journal:  J Endocrinol Invest       Date:  1988-10       Impact factor: 4.256

9.  Effects of naloxone on prolactin, growth hormone and cortisol response to insulin hypoglycemia in obese subjects.

Authors:  D Papalia; M Lunetta; M Di Mauro
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

10.  Plasma beta-endorphin, free fatty acids and blood lipid changes in type 2 (non-insulin dependent) diabetic patients.

Authors:  S B Solerte; M Fioravanti; F Petraglia; F Facchinetti; A L Patti; N Schifino; A R Genazzani; E Ferrari
Journal:  J Endocrinol Invest       Date:  1988-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.